

Li

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Complete if Known

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

| | |
|------------------------|--------------------------------|
| Application Number | Unassigned 10/626, 725 |
| Filing Date | July 25, 2003 |
| First Named Inventor | Christoph-Stephan HILGER et al |
| Group Art Unit | Unassigned 1601 |
| Examiner Name | K. Habre D Jones |
| Attorney Docket Number | SCH-1834C1 |

class/subclass

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document |
|---|-----------------------|----------------------|--------------------------------------|--|---------------------------------------|
| | | Number | Kind Code ² (if known) | | |
|  | 1 | 5,919,797 | | Goodman et al. | 07/06/1999 |
| | 2 | 5,358,712 | | Efange et al. | 10/25/1994 |
| | 3 | 5,721,243 | | Efange et al. | 02/24/1998 |
| | 4 | 6,207,665 | B1 | Bauman et al. | 03/27/2001 |
| | 5 | 5,286,728 | | Ferrini | 02/15/1994 |
| | | | | | |

↓

[illegible]

**Examiner
Signature**

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|--------------------------------|
| Application Number | Unassigned 10/1026725 |
| Filing Date | July 25, 2003 |
| First Named Inventor | Christoph-Stephan HILGER et al |
| Group Art Unit | Unassigned 1614 |
| Examiner Name | K. Habte D. Jones |
| Attorney Docket Number | SCH-1834C1 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|--|----------------|
| | 14 | K. Bergström et al., "Iodine-123 labelled Z-(R,R)-IQNP: a potential radioligand for visualization of M ₁ and M ₂ muscarinic acetylcholine receptors in Alzheimer's disease", European Journal of Nuclear Medicine, Vol. 26, No. 11, pp. 1482-1485, November 1999, XP-002193046 | |
| | 15 | S. Oya et al., "Small and neutral Tc ^{99m} O ₄ BAT, bisaminoethanethiol (N ₂ S ₂) complexes for developing new brain imaging agents", Nuclear Medicine & Biology, Vol. 25, pp. 35-140, 1998 | |
| | 16 | A. Fischman et al., "Rapid detection of parkinson's disease by SPECT with altropane: A selective ligand for dopamine transporters", SYNAPSE, Vol. 29, pp. 128-141, 1998 | |
| | 17 | J. Logan et al., "Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N- ¹¹ C-methyl]-(-)-cocaine PET studies in human subjects", Journal of Cerebral Blood Flow and metabolism, Vol. 10, pp. 740-747, 1990 | |
| | 18 | J. Seibyl et al., "Iodine-123-β-CIT and Iodine-123-FPCIT SPECT measurement of dopamine transporter in healthy subjects and parkinson's patients", The Journal of Nuclear Medicine, Vol. 39, No. 9, pp. 1500-1508, September 1998 | |
| | 19 | M. Melloul et al., "Double-Phase ^{99m} Tc-sestamibi scintimammography and trans-scan in diagnosing breast cancer", The Journal Of Nuclear Medicine, Vol. 40, No. 3, pp. 380, March 1999 | |
| | 20 | J.L. Moretti et al., "Comparison of brain SPECT using ^{99m} Tc-Bicisate (L,L-ECD) and [¹²³ I]IMP in cortical and subcortical strokes", Journal Of Cerebral Blood Flow And Metabolism, Vol. 14 (Suppl. 1), pp. S84-S90, 1994 | |
| | 21 | J.M. Links, "Visual interpretation," Chapter 22 in HN Wagner et al. (Eds.), Principles of Nuclear Medicine, W.B. Saunders Company, 2 nd Edition, 1995, pages 391-392 | |
| | 22 | EL Palmer et al. (Eds.), Practical Nuclear Medicine, Chapter 3 "Cardiovascular Imaging," W.B. Saunders Company, 1992, pp.71-120 | |
| | 23 | International Search Report dated March 28, 2002. | |

Examiner
Signature

Date

Considered

7/12/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.